18 June 2018
Visiongain’ has launched a new pharma report Top 25 Antibiotic Drugs Manufacturers 2018: US, Europe, Japan, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Others
The development of antibacterial resistance has created an opportunity for the drug industry as new anti-infectives are constantly required to target resistant organisms. Currently, a major opportunity lies in the development of drugs required for the treatment of hospital acquired infections and are associated with increased mortality and morbidity. Hence, most of the pharmaceutical companies are recommended to develop combination products to broaden the antibacterial spectrum of activity for combating bacterial resistance.
The lead analyst of the report commented: “Asia-Pacific and RoW are the fastest growing regional markets in the global antibacterial drugs market. Therefore, companies looking to accelerate their overall growth are recommended to invest in these emerging economies and to exploit the untapped growth opportunities available there. Companies are recommended to invest in emerging nations such as India and China, to capitalize on the opportunities available in the form of unmet medical needs, rising disposable incomes of the consumers and increased exposure to improved healthcare facilities.”
Leading companies featured in the report include Pfizer Inc., Merck & Co., Novartis, GSK, Bayer AG, Allergan plc, Shionogi & Co., Ltd., Taisho Pharmaceutical Holdings, Daiichi Sankyo, Sun Pharmaceutical Industries
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
In clinical trials relating to COVID-19, COVID-19 biobanks will play an important role. These biobanks will play an instrumental role in future scientific studies on the emerging coronavirus (COVID-19) pandemic facing the world.
23 October 2020
Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.
19 October 2020
The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.
12 October 2020
We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.